Envoy Medical announced that the United States Patent and Trademark Office granted the company its 40th active U.S. patent, U.S. Patent No. 12,485,288, titled “Cochlear Implant Stimulation Calibration.” The patent protects a system that enables real‑time measurement and adjustment of the electrical current delivered from the implant’s stimulator to the auditory nerve, a core feature of Envoy’s Acclaim Cochlear Implant platform.
The grant adds to a portfolio that now includes 45 foreign patents and reinforces Envoy’s competitive moat in the fully implanted hearing‑device market. By securing additional protection for its key technology, Envoy positions itself to defend against competitors and to streamline future regulatory and reimbursement processes for the Acclaim product, which received FDA Breakthrough Device Designation in 2019.
The Acclaim cochlear implant is currently in a U.S. pivotal clinical trial. All 10 patients in the first stage of the trial have completed their six‑month follow‑up visits with encouraging results and no serious adverse events. FDA approval to expand the trial to its final stage has also been granted, giving Envoy a clearer path toward eventual market entry.
Financially, Envoy remains in a development phase. Net revenue for the third quarter of 2025 was $42,000, a decline from prior periods, and the company posted a net loss of $5.69 million. For the full year 2024, revenue was $225,000, down 28.8% from 2023, and losses totaled $27.97 million. The company has been working to strengthen its balance sheet, extinguishing over $32 million in debt, but it continues to face significant cash burn as it advances the Acclaim program.
CEO Brent Lucas emphasized the strategic importance of the patent grant, saying, “Imagine where we could be in another couple of years as new patents issue and we expand upon what we already have. We will continue our commitment to the future of hearing devices and look forward to what our team will think of next.” The comment underscores Envoy’s focus on long‑term innovation while acknowledging the current financial headwinds.
The patent announcement, coupled with the positive early clinical data, signals progress in Envoy’s core technology and may enhance investor confidence in the company’s long‑term trajectory, even as it continues to navigate the challenges of a development‑stage medical‑device business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.